

A Smarter Model For Cancer Therapy

Our “3-S” cancer therapeutics are built to improve patient outcomes without adding complexity.



All Rights Reserved. 2025

A Clinical-Stage Biotechnology Company



Company Overview

Why Us? Why Now?

The Problem: Oncology innovation can be complex, costly, and high-risk

Our Solution: JBZ-001 strategically simplifies cancer care: Potent, convenient, scalable, synergistic with high-value therapies.

Significant Impact and Market Opportunity

Derisked Asset: Validated DHODH biology with clear precedent.

High-Value Markets: Compelling synergy data, and strategic clinical positioning create a clear path into attractive AML and MM markets.

Clear Near-Term Value Inflection & Long-Term Potential

Near Term: Active Phase I trial rapidly approaching key milestones

Long-Term: Strong pharma partnering potential, and an experienced team maximizing investor value.



Location: Cranberry TWP, PA, USA

Founded: March 2025

© 2025



World-Class Leadership Team



Tamara Jovonovich, PhD, CEO

20 years in pharmaceutical development; 15 FDA drug approvals



Rob Lewis, COO

30 years in pharmaceutical development; 30 FDA drug approvals



Brian Cogley, CFO

Over 15 years leading companies in various industries including life sciences and financial services

Scientific Affiliations

The James




THE OHIO STATE UNIVERSITY
COMPREHENSIVE CANCER CENTER

The Problem: Innovation Can Be Complex

The oncology industry seems to be trapped in a scenario where meaningful progress sometimes requires **extreme complexity, high costs, and substantial risks.**

Some innovation is complex...



...we still need options that are:

Effective

Convenient


Safe

Affordable

Our Solution: Strategic Simplicity

Our lead asset, JBZ-001, directly addresses this challenge. It is a small molecule inhibitor of DHODH, explicitly designed around these critical industry needs.

JBZ-001, is:





Safe, Convenient, Scalable + Rational Synergy = High-Value Asset!!

JBZ-001: Validated, Derisked Biology








JBZ-001 inhibits DHODH – a clear, and well-validated target with decades of precedent. Multiple FDA approved DHODH inhibitors for autoimmunity.

JBZ-001: Mechanism of Action



Our Edge: Superior Therapeutic Properties

JBZ-001 is uniquely positioned as a high-value asset in oncology, combining superior therapeutic qualities with a clinically validated mechanism.

Enzyme inhibition		
Developer	Platform	IC ₅₀ (nM)
	JBZ-001	0.95
 Bayer	BAY	0.97
	A-636	3.38
	ASLAN003	3.91
	Teriflunomide	26.45
	Leflunomide	208.5
	PTC299	686.5

While potency is highlighted here, JBZ-001 also exhibits superior pharmacokinetics, extended half-life, and excellent oral bioavailability – key attributes critical for effective small molecule therapeutics.

Approved for RA and MS, respectively.

JBZ-001 is exponentially more potent*

Once-daily
AUBAGIO®
(teriflunomide) 14 mg tablets
* AUBAGIO (R) is available in 14 mg and 7 mg tablets.



Elgamal and Fobare, et al., JCI Insights 2024

Clinical Strategy: Establish Safety, Then Expand

Our ongoing Phase I trial efficiently establishes JBZ-001's safety and dosing in advanced solid tumors and NHL—paving the way for rapid strategic expansion into targeted, high-value oncology indications



Study Details

Ph1a to include all-comers solid tumor + non-Hodgkins Lymphoma (NHL)

- Advanced/metastatic solid tumors may include small cell lung cancer, colorectal cancer, pancreatic cancer, Gastric cancer
- Ph 1 pt a: Safety and tolerability, prelim efficacy; MTD, 15- 20 patients
- Ph 1 pt b: Dose Escalation; up to 4-indications, OBD, 40-80+ patients
- Planned dose Expansion into relapsed/refractory heme malignancies multiple myeloma (MM), Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS)

Favorable Phase I Design in Oncology

Phase I trial will quickly reveal early efficacy signals alongside safety data.

Market Opportunity: High-Value Disease Types

JBZ-001 strategically addresses multiple hematologic and solid tumor indications through a unified, validated mechanism – positioning it as a high-value oncology asset.

Clinical testing ongoing:

Lymphoma (target: NHL)

Expected to grow from \$10.11B in 2024 to \$15.4B in 2029¹

Phase I enrollment underway; JBZ-001's validated metabolic target broadly applicable.

Various Solid Tumors

Anticipated to reach \$442.8B by 2029, up from \$232.2B in 2024²

Initial Phase I safety and preliminary efficacy signals being established broadly.

Trials soon to commence:

Leukemia (target: AML)

Estimated at \$3.47B in 2024, with a CAGR of 10.6% through 2030³

JBZ-001 induces differentiation of AML cells, strategically enhancing efficacy of approved drugs.


Myeloma (target: MM)

Projected to reach \$30.3B by 2033, from \$22.6B in 2024⁴

JBZ-001 significantly boosts CD38 expression, strongly synergizing with approved antibodies.

Why Invest Now?

Jabez is entering an **inflection point** event triggering **exponential growth** via pharma partnerships, acquisitions, and other near-term exit opportunities.





Thank You!

Safe, Scalable, Synergistic Cancer Therapeutics

A Clinical-Stage Biotechnology Company

All Rights Reserved. 2025

References

- 1 <https://www.researchandmarkets.com/reports/5865929/non-hodgkin-lymphoma-nhl-market-report?srsId=AfmBOorHpJMSlC6T9kccHmb6t5-vvml6CoUt9SPLnquxaxmn2u4yIf4Y&utm>
- 2 <https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report?utm>
- 3 <https://www.grandviewresearch.com/industry-analysis/acute-myeloid-leukemia-therapeutics-market>
- 4 <https://www.globenewswire.com/news-release/2025/05/15/3082504/0/en/Global-Multiple-Myeloma-Market-Size-To-Reach-USD-30-3-Billion-by-2033-Says-Astute-Analytica.html>

- 1 <https://www.researchandmarkets.com/reports/5865929/non-hodgkin-lymphoma-nhl-market-report?srsId=AfmBOorHpJMSlC6T9kccHmb6t5-vvml6CoUt9SPLnquxaxmn2u4ylf4Y&utm>
- 2 <https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report?utm>
- 3 <https://www.grandviewresearch.com/industry-analysis/acute-myeloid-leukemia-therapeutics-market>
- 4 <https://www.globenewswire.com/news-release/2025/05/15/3082504/0/en/Global-Multiple-Myeloma-Market-Size-To-Reach-USD-30-3-Billion-by-2033-Says-Astute-Analytica.html>